Figure 2 — Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Research Paper|Volume 16, Issue 19|pp. 12769–12780

Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Back to articleFigure 2(2 of 7)

100%

Figure 2.Bezafibrate ameliorated release of the myocardial injury indicators in CME rats. (A) The CK-MB level; (B) The AST level; (C) The LDH level (n=12, ^**, p<0.01 vs. control group; ^#, ^##, p<0.05, 0.01 vs. CME group).